Cytomegalovirus retinitis in the era of combined highly active antiretroviral therapy

Robert F See; Narsing A Rao

doi:10.1016/s0896-1549(02)00048-2

Cytomegalovirus retinitis in the era of combined highly active antiretroviral therapy

Ophthalmol Clin North Am. 2002 Dec;15(4):529-36, viii. doi: 10.1016/s0896-1549(02)00048-2.

Authors

Robert F See¹, Narsing A Rao

Affiliation

¹ Department of Ophthalmology, Doheny Eye Institute, Keck School of Medicine, University of Southern California, 1450 San Pablo Street, DVRC 211, Los Angeles, CA 90033, USA.

PMID: 12515085
DOI: 10.1016/s0896-1549(02)00048-2

Abstract

Advancements in antiretroviral therapy have changed the way we view and treat cytomegalovirus retinitis (CMVR). At one time the diagnosis of CMVR necessitated that most patients undergo daily intravenous infusions of anti-CMV agents. Today, after the restoration of their immune systems, they are able to stop maintenance anti-CMV therapy. HAART failure, resistant strains of CMV, and immune recovery uveitis are growing challenges.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review

MeSH terms

AIDS-Related Opportunistic Infections / drug therapy*
Antiretroviral Therapy, Highly Active*
Antiviral Agents / therapeutic use
Cytomegalovirus Retinitis / drug therapy*
Humans

Substances

Antiviral Agents

Grants and funding

EY03040/EY/NEI NIH HHS/United States